Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | MAOB | P27338 | 2/20 | 0.36 |
| ▸ | MAOA | P21397 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | THPO | P40225 | 1/20 | 0.36 |
| ▸ | MTOR | P42345 | 1/20 | 0.36 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.35 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.35 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.35 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.35 |
| ▸ | BCHE | P06276 | 1/20 | 0.35 |
| ▸ | ACHE | P22303 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23396338 | 0.98 | ALDH1A1 (0.41) | ALDH1A1MAOB | |
| SCHEMBL13656252 | 0.91 | KDM4E (0.38) | ALDH1A1MAOBCYP3A4CYP2D6CHRM2 | |
| SCHEMBL823834 | 0.81 | MEN1 (0.41) | CYP2D6CHRM2CHRM4CHRM1CHRM3 | |
| SCHEMBL26004844 | 0.81 | KDM4E (0.32) | ALDH1A1CYP3A4CYP2D6CHRM2CHRM1 | |
| SCHEMBL12380889 | 0.81 | CHRM2 (0.33) | CHRM2 | |
| SCHEMBL23396341 | 0.78 | KDM5A (0.33) | CHRM2 | |
| SCHEMBL13538316 | 0.78 | MAPK1 (0.35) | ALDH1A1 | |
| SCHEMBL19193963 | 0.78 | MAPK1 (0.35) | ALDH1A1 | |
| SCHEMBL12361992 | 0.78 | MAPK1 (0.35) | ALDH1A1 | |
| SCHEMBL27240066 | 0.78 | MAPK1 (0.35) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11013696-B2 | Lipids and lipid compositions for the delivery of active agents | NOVARTIS AG (CH) | 2021-05-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11013696-B2 | Lipids and lipid compositions for the delivery of active agents | PHOSPHO1, SGMS1, LIPA | ALDH1A1 1564/4885MAOB 4526/4885MAOA 4690/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.